United States research-based biopharmaceutical company AbbVie Inc. (NYSE: ABBV) announced on Friday its quarterly cash dividend.
The company has declared a quarterly cash dividend of USD1.55 per share. The dividend will be paid to shareholders of record as at 15 October 2024, on 15 November 2024.
AbbVie focuses on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and women's health, as well as through our Allergan Aesthetics portfolio.
hVIVO acquires German Clinical Research Units for EUR10m; Targets earnings growth by 2026
OptiBiotix expands into Indian market with Amazon launch
Poxel to receive royalties and sales-based payment from Sumitomo Pharma
ReciBioPharm secures grant to expand RNA manufacturing in LMICs
CVS Health to pays common stock quarterly dividend of USD0.665 per share
TC BioPharm receives shareholders' approval for 25% stock dividend
USANA Health Sciences acquires controlling stake in Hiya Health for USD205m
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Moberg Pharma's MOB-015 fails to meet primary endpoint in phase 3 study
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine
Lakeside's Sichuan Hupan to acquire Hupan Pharmaceutical
Cardinal Health to pay quarterly dividend of USD0.5056 per share